We are delighted to announce our first achievement in 2024.
As of yesterday (01/25/24), SIRP-EV achieved an Orphan Drug Designation (ODD) for acute liver failure (severe acute liver injury) from the US FDA. This designation is a significant milestone for us, affirming ALI's high unmet medical needs and the US FDA's acknowledgment of SIRP-EV's potential as a therapeutic solution.
At SHIFTBIO, we are dedicated to advancing innovative drug development based on our ESM platform, striving to persistently offer new opportunities to patients.
We are delighted to announce our first achievement in 2024.
As of yesterday (01/25/24), SIRP-EV achieved an Orphan Drug Designation (ODD) for acute liver failure (severe acute liver injury) from the US FDA. This designation is a significant milestone for us, affirming ALI's high unmet medical needs and the US FDA's acknowledgment of SIRP-EV's potential as a therapeutic solution.
At SHIFTBIO, we are dedicated to advancing innovative drug development based on our ESM platform, striving to persistently offer new opportunities to patients.